Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
Would you recommend starting an SGLT-2 inhibitors in patients with non-severe aortic stenosis based on recent evidence suggesting it may slow progression of disease?
Shah T, et al. PMID 39985508
Related Questions
In patients with contraindications to TEE and poor windows for TTE, what is the next best test to look for PFO?
How do you decide the duration of DAPT following TAVR, especially for patients already on a DOAC?
What is the optimal anti-platelet/anticoagulant strategy and duration following a left atrial appendage occlusion with a watchmen device and is a CTA good enough to assess if the device is well seated and without any peri device leaks?
What is the best approach to asymptomatic severe primary tricuspid regurgitation when imaging begins to show RV enlargement?
For asymptomatic, incidentally found Lambl's excrescence, should long-term surveillance imaging be considered and if so, how often should repeat imaging be ordered?
In a patient with suspected prosthetic valve endocarditis, how long after prosthetic valve implantation is an FDG PET reasonable to rule out infection?
Are there any indications for valve intervention in asymptomatic patients with moderate AS?
Would it be reasonable to consider combined BAV plus staged PCI in a patient presenting with ACS and new LV systolic dysfunction, moderate aortic stenosis, and complex bifurcating left main disease and RCA CTO?
How would you approach the INR goal in a patient with mechanical aortic valve and high bleeding risk factors like immune thrombocytopenia, AV malformations and recurrent GI bleeds, etc.?
In a patient with severe TR, when is the best time to start thinking about T-TEER?
